Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ionising radiation such as X-rays, gamma rays, and heavy ions induces DNA damage through direct ionization and generation of reactive oxygen species (ROS), leading to base damage, single-strand breaks, double-strand breaks, abasic sites, and complex clustered lesions. Clustered DNA damage, especially complex DSBs, is particularly lethal and poorly repaired, driving cell death, genomic instability, and carcinogenesis. This damage response is the basis for radiotherapy efficacy in cancer treatment, as tumor cells rely on DNA repair mechanisms to survive. Tumor selectivity and radiosensitivity are influenced by repair pathway choices, and therapeutic agents may enhance or protect against radiation-induced DNA damage by modulating these pathways.
Radiosensitizers: inhibit DNA repair proteins, increase DNA damage lethality Radioprotectors: scavenge free radicals, minimize DNA damage
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA damage induced by ionising radiation.